Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Gut Peptide Agonism in the Treatment of Obesity and Diabetes.

Tytuł :
Gut Peptide Agonism in the Treatment of Obesity and Diabetes.
Autorzy :
Grandl G; Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Neuherberg, Germany.; German Center for Diabetes Research (DZD), Neuherberg, Germany.
Novikoff A; Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Neuherberg, Germany.; German Center for Diabetes Research (DZD), Neuherberg, Germany.
DiMarchi R; Department of Chemistry, Indiana University, Bloomington, Indiana, USA.
Tschöp MH; German Center for Diabetes Research (DZD), Neuherberg, Germany.; Division of Metabolic Diseases, Technische Universität München, Munich, Germany.
Müller TD; Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Neuherberg, Germany.; German Center for Diabetes Research (DZD), Neuherberg, Germany.; Department of Pharmacology and Experimental Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology, Eberhard Karls University Hospitals and Clinics, Tübingen, Germany.
Pokaż więcej
Źródło :
Comprehensive Physiology [Compr Physiol] 2019 Dec 18; Vol. 10 (1), pp. 99-124. Date of Electronic Publication: 2019 Dec 18.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
Język :
English
MeSH Terms :
Diabetes Mellitus, Type 2/*drug therapy
Gastrointestinal Hormones/*agonists
Obesity/*drug therapy
Peptides/*agonists
Animals ; Bariatric Surgery ; Diabetes Mellitus, Type 2/metabolism ; Gastrointestinal Hormones/metabolism ; Humans ; Obesity/metabolism ; Obesity/surgery ; Peptides/metabolism
Substance Nomenclature :
0 (Gastrointestinal Hormones)
0 (Peptides)
Entry Date(s) :
Date Created: 20191220 Date Completed: 20200903 Latest Revision: 20200903
Update Code :
20210301
DOI :
10.1002/cphy.c180044
PMID :
31853954
Czasopismo naukowe
Obesity is a global healthcare challenge that gives rise to devastating diseases such as the metabolic syndrome, type-2 diabetes (T2D), and a variety of cardiovascular diseases. The escalating prevalence of obesity has led to an increased interest in pharmacological options to counteract excess weight gain. Gastrointestinal hormones such as glucagon, amylin, and glucagon-like peptide-1 (GLP-1) are well recognized for influencing food intake and satiety, but the therapeutic potential of these native peptides is overall limited by a short half-life and an often dose-dependent appearance of unwanted effects. Recent clinical success of chemically optimized GLP-1 mimetics with improved pharmacokinetics and sustained action has propelled pharmacological interest in using bioengineered gut hormones to treat obesity and diabetes. In this article, we summarize the basic biology and signaling mechanisms of selected gut peptides and discuss how they regulate systemic energy and glucose metabolism. Subsequently, we focus on the design and evaluation of unimolecular drugs that combine the beneficial effects of selected gut hormones into a single entity to optimize the beneficial impact on systems metabolism. © 2020 American Physiological Society. Compr Physiol 10:99-124, 2020.
(Copyright © 2019 American Physiological Society. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies